Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
28
¥100 million (year-on-year increase in net sales)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentation materialsFirst half of the fiscal year ending March 2027 (second quarter)11 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥175.6 100 million+19.0%
Operating profit¥15.5 100 million+3,150.0%
Ordinary income¥30.8 100 million+89.3%
Net income¥21.9 100 million+107.1%
Gross Profit Margin49.9 %
Operating profit margin8.9 %
Selling, general and administrative expenses¥7,208 million
Full-year earnings forecast
Net Sales
¥380 100 million
Operating profit
¥30 100 million
Ordinary income
¥60 100 million
Profit attributable to owners of the parent
¥35 100 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue and profit both exceeded the revised first-half forecastsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue¥2,801 million
- Increase in costs of sales¥715 million
- Increase in labor costs¥1,129 million
- Higher depreciation expense¥191 million
- Increase in selling, general and administrative expenses¥580 million
- Decrease in R&D Expenses¥-877 million
- Decrease in farm management costs¥-206 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate (US dollar)¥150
New initiatives
- Building the manufacturing, distribution and sales infrastructure for the launch of Atzumi sales in the United States in the second half of 2027
- Demonstration of next-generation geothermal power generation using a “closed-loop system” with Mitsui Fudosan and others
- Initiatives toward the mass production and commercialization of artificial glass eels
Key KPIsA metric the company considers important as a management benchmark.
- Non-clinical bookings¥19,641 million
- Non-clinical order backlog¥43,784 million
- Overseas bookings as a percentage of total bookings54 %
- Overseas order backlog as a percentage of total backlog51.7 %
- Overseas customer repeat rate98 %
- Number of companies with contracts or specific inquiries among companies ranked within the top 25 worldwide by sales13 companies
- Value of inquiries¥267.6 100 million
Segment results
- CRO BusinessNet Sales¥16,929 millionOperating profit¥4,009 millionYear-on-Year Change in Revenue (%)19.7Operating profit year-on-year_pct81.7
- Translational Research BusinessNet Sales¥90 millionOperating profit¥-2,097 million
- Medipolis BusinessNet Sales¥407 millionOperating profit¥-70 millionYear-on-Year Change in Revenue (%)4.4
- U.S. Real EstateNet Sales¥97 millionOperating profit¥-68 millionYear-on-Year Change in Revenue (%)10.2
- Other businesses and eliminationsNet Sales¥42 millionOperating profit¥-218 million
Orders received and order backlog
Orders received
¥196.41 100 million
Order backlog
¥437.84 100 million
Number of employees
1,676 people
Capital expenditures
¥110.86 100 million full-year forecast
Annual Dividend
¥50 per share
Payout ratio
59.5 %
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | First half of the fiscal year ending March 2027 (second quarter) |
| Net Sales | ¥175.6 100 million (YoY +19.0%) |
| Operating profit | ¥15.5 100 million (YoY +3,150.0%) |
| Ordinary income | ¥30.8 100 million (YoY +89.3%) |
| Net income | ¥21.9 100 million (YoY +107.1%) |
| Gross Profit Margin | 49.9 % |
| Operating profit margin | 8.9 % |
| Selling, general and administrative expenses | ¥7,208 million |
| Full-year earnings forecast | Net Sales ¥380 100 million / Operating profit ¥30 100 million / Ordinary income ¥60 100 million / Profit attributable to owners of the parent ¥35 100 million |
| Self-assessment against the plan | Revenue and profit both exceeded the revised first-half forecasts |
| Segment results | Segment CRO Business / Net Sales ¥16,929 million / Operating profit ¥4,009 million / Year-on-Year Change in Revenue (%) 19.7 / Operating profit year-on-year_pct 81.7, Segment Translational Research Business / Net Sales ¥90 million / Operating profit ¥-2,097 million, Segment Medipolis Business / Net Sales ¥407 million / Operating profit ¥-70 million / Year-on-Year Change in Revenue (%) 4.4, Segment U.S. Real Estate / Net Sales ¥97 million / Operating profit ¥-68 million / Year-on-Year Change in Revenue (%) 10.2, Segment Other businesses and eliminations / Net Sales ¥42 million / Operating profit ¥-218 million |
| Breakdown of Factors Affecting the Change | Factors Increase in revenue / Amount ¥2,801 million, Factors Increase in costs of sales / Amount ¥715 million, Factors Increase in labor costs / Amount ¥1,129 million, Factors Higher depreciation expense / Amount ¥191 million, Factors Increase in selling, general and administrative expenses / Amount ¥580 million, Factors Decrease in R&D Expenses / Amount ¥-877 million, Factors Decrease in farm management costs / Amount ¥-206 million |
| Key KPIs | Non-clinical bookings ¥19,641 million, Non-clinical order backlog ¥43,784 million, Overseas bookings as a percentage of total bookings 54 %, Overseas order backlog as a percentage of total backlog 51.7 %, Overseas customer repeat rate 98 %, Number of companies with contracts or specific inquiries among companies ranked within the top 25 worldwide by sales 13 companies, Value of inquiries ¥267.6 100 million |
| Number of employees | 1,676 people |
| Assumptions Underlying the Business Outlook | Exchange rate (US dollar) ¥150 |
| Annual Dividend | ¥50 per share |
| Payout ratio | 59.5 % |
| Capital expenditures | ¥110.86 100 million (full-year forecast) |
| Orders received and order backlog | Orders received ¥196.41 100 million / Order backlog ¥437.84 100 million |
| New initiatives | Building the manufacturing, distribution and sales infrastructure for the launch of Atzumi sales in the United States in the second half of 2027, Demonstration of next-generation geothermal power generation using a “closed-loop system” with Mitsui Fudosan and others, Initiatives toward the mass production and commercialization of artificial glass eels |
Items this document does not state (10)
Results for the three months of the current quarterProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main reason for the revenue increase was that several CRO projects scheduled to be recognized during the previous fiscal year shifted into the first half under review. In addition to higher revenue, the shift of TR business expenses into the second half also contributed to profit improvement.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.